Journal ArticleDOI
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
Reads0
Chats0
TLDR
The findings suggest that the previously reported associated between an early age at first exposure and the risk of inhibitor development is largely explained by early, intensive treatment, and early, regular prophylaxis may protect patients with hemophilia against the development of inhibitors.Citations
More filters
Journal ArticleDOI
Management of severe perioperative bleeding Guidelines from the European Society of Anaesthesiology
Sibylle A. Kozek-Langenecker,Arash Afshari,Pierre Albaladejo,Cesar Aldecoa Alvarez Santullano,Edoardo De Robertis,Daniela Filipescu,Dietmar Fries,Thorsten Haas,Georgina Imberger,Matthias Jacob,Marcus D. Lancé,Juan V. Llau,Susan Mallett,Jens Meier,Niels Rahe-Meyer,Charles Marc Samama,Andrew Smith,Cristina Solomon,Philippe Van der Linden,Anne Wikkelsø,Patrick Wouters,Piet Wyffels +21 more
TL;DR: These guidelines are intended to provide an overview of current knowledge on the subject with an assessment of the quality of the evidence in order to allow anaesthetists throughout Europe to integrate this knowledge into daily patient care wherever possible.
Journal ArticleDOI
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Samantha C. Gouw,Johanna G. van der Bom,Rolf Ljung,Carmen Escuriola,Ana Rosa Cid,Ségolène Claeyssens-Donadel,Christel Van Geet,Gili Kenet,Anne Mäkipernaa,Angelo Claudio Molinari,Wolfgang Muntean,Rainer Kobelt,George E Rivard,E. Santagostino,Angela Thomas,H. Marijke van den Berg +15 more
TL;DR: Recombinant and plasma-derived factor VIII products conferred similar risks of inhibitor development, and the content of von Willebrand factor in the products and switching among products were not associated with the risk of inhibitors development.
Journal ArticleDOI
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
Flora Peyvandi,Pier Mannuccio Mannucci,Isabella Garagiola,Amal El-Beshlawy,Mohsen Saleh Elalfy,Vijay Ramanan,Peyman Eshghi,Suresh Hanagavadi,Ramabadran Varadarajan,Mehran Karimi,Mamta Manglani,Cecil Ross,Guy Young,Tulika Seth,Shashikant Apte,Dinesh M Nayak,E. Santagostino,Maria Elisa Mancuso,Adriana C Sandoval Gonzalez,Johnny Mahlangu,Santiago Bonanad Boix,M. Cerqueira,Nadia P. Ewing,Christoph Male,Tarek Owaidah,Veronica Soto Arellano,Nathan L Kobrinsky,Suvankar Majumdar,Rosario Perez Garrido,Anupam Sachdeva,Mindy L. Simpson,Mathew Thomas,Ezio Zanon,Bülent Antmen,Kaan Kavakli,Marilyn J. Manco-Johnson,Monica Martinez,Esperanza Marzouka,Maria Gabriella Mazzucconi,Daniela Neme,Angeles Palomo Bravo,Rogelio Paredes Aguilera,Alessandra Nunes Loureiro Prezotti,Klaus Schmitt,Brian M. Wicklund,Bulent Zulfikar,Frits R. Rosendaal +46 more
TL;DR: Patients treated with plasma-derived factor VIII containing von Willebrand factor had a lower incidence of inhibitors than those treated with recombinant factor VIII, and this association did not change in multivariable analysis.
Journal ArticleDOI
The past and future of haemophilia: diagnosis, treatments, and its complications.
TL;DR: Treatment for haemophilia A and B might improve considerably with the availability of new modified drugs, which might overcome existing prophylaxis limitations by reducing dosing frequency and thereby rendering therapy less distressing for the patient.
Journal ArticleDOI
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
Samantha C. Gouw,Samantha C. Gouw,H. Marijke van den Berg,Johannes Oldenburg,Jan Astermark,Philip G. de Groot,Maurizio Margaglione,Arthur R. Thompson,Waander L. van Heerde,Jorien Boekhorst,Connie H. Miller,Saskia le Cessie,Johanna G. van der Bom +12 more
TL;DR: The primary outcome was inhibitor development and the secondary outcome was high-titer-inhibitor development, and the relative risks for developing high titer inhibitors were similar.
References
More filters
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
The Danger Model: A Renewed Sense of Self
TL;DR: A model of immunity based on the idea that the immune system is more concerned with entities that do damage than with those that are foreign is outlined.
Journal ArticleDOI
Continuing positive secular growth change in the Netherlands 1955-1997
A.M. Fredriks,S. van Buuren,R.J.F. Burgmeijer,J.F. Meulmeester,R.J. Beuker,E. Brugman,M.J. Roede,S.P. Verloove-Vanhorick,Jan M. Wit +8 more
TL;DR: A positive secular growth change has been present in the past 42 y for children, adolescents, and young adults of Dutch origin, although at a slower rate in the last 17 y.
Journal ArticleDOI
Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study.
Ralph B. D'Agostino,Mei-Ling Lee,Albert J. Belanger,L. Adrienne Cupples,Keaven M. Anderson,William B. Kannel +5 more
TL;DR: Numerical examples covering a variety of sample sizes and proportions of events display the closeness of this relationship in situations typical of the Framingham Study.
Journal ArticleDOI
The epidemiology of inhibitors in haemophilia A: a systematic review.
J Wight,Suzy Paisley +1 more
TL;DR: A systematic review of the best available evidence relating to the epidemiology of inhibitors in haemophilia A found that prevalence and cumulative incidence data should be used to estimate the likely demand for treatments aimed at eliminating inhibitors.
Related Papers (5)
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Marilyn J. Manco-Johnson,Marilyn J. Manco-Johnson,Thomas C. Abshire,Amy D. Shapiro,Brenda Riske,Michele R. Hacker,Ray F. Kilcoyne,J. David Ingram,M L Manco-Johnson,Sharon Funk,Linda J. Jacobson,Leonard A. Valentino,W. Keith Hoots,George R. Buchanan,Donna DiMichele,Michael Recht,Deborah L Brown,Cindy A. Leissinger,Shirley Bleak,Alan R. Cohen,Prasad Mathew,Alison Matsunaga,Desiree Medeiros,Diane J. Nugent,Gregory Thomas,Alexis A. Thompson,Kevin McRedmond,J. Michael Soucie,Harlan Austin,Bruce L. Evatt +29 more
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
Samantha C. Gouw,H. Marijke van den Berg,Krista Fischer,Guenter Auerswald,Manuel Carcao,Elizabeth Chalmers,Hervé Chambost,Karin Kurnik,Ri Liesner,Pia Petrini,Helen Platokouki,Carmen Altisent,Johannes Oldenburg,Beatrice Nolan,Rosario Perez Garrido,M Elisa Mancuso,Anne Rafowicz,Michael Williams,Niels Clausen,Rutger A. Middelburg,Rolf Ljung,Johanna G. van der Bom +21 more